Clients
“Cellectar and AtomVie (CPDC at the time) have been working together since 2016 to manufacture CLR-131 and bring this compound to market. Through ...” Read more
“Precirix and AtomVie (CPDC at the time) have been on this journey starting from early development up until clinical supply of CAM-H2 for ...” Read more
“AtomVie, and CPDC before it, has been a great partner to POINT. Their support in the submission of our Canadian Clinical Trial applications ...” Read more
“AtomVie and Isotopia are working relentlessly to secure an uninterrupted and redundant supply of n.c.a. Lu-177 for manufacturing innovative radiotherapeutics, enabling timely treatments ...” Read more
“AtomVie’s expertise and passion for nuclear medicine are truly inspiring for CellBion. We are delighted to be working with such an expert team, ...” Read more
“Cellectar and AtomVie (CPDC at the time) have been working together since 2016 to manufacture CLR-131 and bring this compound to market. Through their successful track record, AtomVie has proven that they are an excellent manufacturing solution for us to take on a long-term and sustainable journey. AtomVie with their diligence, commitment, and unique expertise working with I-131, has made us confident in their abilities to assist us in supplying and commercializing CLR-131.”
“Precirix and AtomVie (CPDC at the time) have been on this journey starting from early development up until clinical supply of CAM-H2 for more than 6 years. Time is a testimony to the trust we have established in this partnership as AtomVie has shown true professionalism with their transparency and devotion. We look forward to continuing our journey by making a positive impact on patients’ lives through the supply of CAM-H2 and future endeavors”
“AtomVie, and CPDC before it, has been a great partner to POINT. Their support in the submission of our Canadian Clinical Trial applications for our radioligand programs has been instrumental in accelerating our pipeline of next generation radioligand therapies.”
“AtomVie and Isotopia are working relentlessly to secure an uninterrupted and redundant supply of n.c.a. Lu-177 for manufacturing innovative radiotherapeutics, enabling timely treatments and subsequently the improvement of patients' lives globally. AtomVie(CPDC at the time) and Isotopia established a unique partnership where we leveraged other's expertise and succeeded in setting up a reliable source of n.c.a. Lu-177 at AtomVie for North American supply. The AtomVie team is professional, highly experienced, and delivers top-quality results in an efficient manner.”
“AtomVie's expertise and passion for nuclear medicine are truly inspiring for CellBion. We are delighted to be working with such an expert team, whose attention to detail and dedication to making our product stability better are greatly appreciated. Our collaboration has been a key factor in the significant improvement of the CellBion product stability and the support of the AtomVie team was essential in achieving what we have today. At the core of our mission is the desire to help patients in need and CellBion believes that with our collaboration with AtomVie, we can make a difference.”